Perimenopausal vaginal bleeding: Diagnostic evaluation and therapeutic options

Journal of Women's Health

Volumn 21, Issue 3, 2012, Pages 302-310

  Chaudhry, Sonal ^a   Berkley, Cynthia ^a   Warren, Michelle ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; DANAZOL; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; FOLLITROPIN; GESTAGEN; GONADORELIN AGONIST; GONADOTROPIN; LEVONORGESTREL; LUTEINIZING HORMONE; MEDROXYPROGESTERONE ACETATE; MEFENAMIC ACID; MUELLERIAN INHIBITING FACTOR; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; TRANEXAMIC ACID;

ABDOMINAL PAIN; AMENORRHEA; ANEMIA; ANOVULATION; BACTERIUM CULTURE; BLOATING; BLOOD TRANSFUSION; BONE DENSITY; BREAKTHROUGH BLEEDING; BREAST TENDERNESS; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; CRYOTHERAPY; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DYSPEPSIA; ENDOMETRIUM ABLATION; ENDOMETRIUM BIOPSY; ENDOMETRIUM HYPERPLASIA; FATIGUE; GASTROINTESTINAL SYMPTOM; HEALTH CARE PERSONNEL; HORMONE RESPONSE; HUMAN; HYSTERECTOMY; HYSTEROSCOPY; IRON THERAPY; LABORATORY TEST; LOW DRUG DOSE; MEDICAL HISTORY; MENOPAUSAL SYNDROME; MENSTRUAL CYCLE; MENSTRUAL IRREGULARITY; MENSTRUATION; METRORRHAGIA; MICROWAVE THERAPY; MOOD CHANGE; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOLYSIS; PAPANICOLAOU TEST; PATIENT ASSESSMENT; PELVIC EXAMINATION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; REVIEW; SIDE EFFECT; THROMBOSIS; TRANSVAGINAL ECHOGRAPHY; ULTRASOUND SURGERY; UNSPECIFIED SIDE EFFECT; UTERINE ARTERY EMBOLIZATION; VAGINA BLEEDING; VENOUS THROMBOEMBOLISM; VOMITING; WEIGHT CHANGE; WOMEN'S HEALTH;

FEMALE; HUMANS; MIDDLE AGED; PREMENOPAUSE; UTERINE HEMORRHAGE;

EID: 84858117651     PISSN: 15409996     EISSN: 1931843X     Source Type: Journal    
DOI: 10.1089/jwh.2011.2949     Document Type: Review

References (72)

1. Soules MR, Sherman S, Parrott E, et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW). Climacteric 2001;4:267-272. (Pubitemid 34002968)
2. Cramer DW, Barbieri RL, Xu H, Reichardt JK. Determinants of basal follicle-stimulating hormone levels in premenopausal women. J Clin Endocrinol Metab 1994;79:1105-1109. (Pubitemid 24342256)
3. McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. Maturitas 1992;14:103-115.
4. Gold EB, Bromberger J, Crawford S, et al. Factors associated with age at natural menopause in a multiethnic sample of midlife women. Am J Epidemiol 2001;153:865-874. (Pubitemid 32378620)
5. Dickersin K, Munro MG, Clark M, et al. Hysterectomy compared with endometrial ablation for dysfunctional uterine bleeding: a randomized controlled trial. Obstet Gynecol 2007;110:1279-1289. (Pubitemid 351326070)
6. Broekmans FJ, Soules MR, Fauser BC. Ovarian aging: mechanisms and clinical consequences. Endocr Rev 2009;30:465-493.
7. Freeman EW, Sammel MD, Gracia CR, et al. Follicular phase hormone levels and menstrual bleeding status in the approach to menopause. Fertil Steril 2005;83:383-392. (Pubitemid 40221793)
8. Burger HG, Cahir N, Robertson DM, et al. Serum inhibins A and B fall differentially as FSH rises in perimenopausal women. Clin Endocrinol (Oxf) 1998;48:809-813. (Pubitemid 28289252)
9. Burger HG, Hale GE, Dennerstein L, Robertson DM. Cycle and hormone changes during perimenopause: the key role of ovarian function. Menopause 2008;15:603-612.
10. Hale GE, Burger HG. Hormonal changes and biomarkers in late reproductive age, menopausal transition and menopause. Best Pract Res Clin Obstet Gynaecol 2009;23:7-23.
11. Burger HG, Dudley EC, Hopper JL, et al. The endocrinology of the menopausal transition: a cross-sectional study of a population-based sample. J Clin Endocrinol Metab 1995;80:3537-3545.
12. van Rooij IA, Broekmans FJ, Scheffer GJ, et al. Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril 2005;83:979-987.
13. te Velde ER, Pearson PL. The variability of female reproductive ageing. Hum Reprod Update 2002;8:141-154. (Pubitemid 34428965)
14. Sowers MR, Eyvazzadeh AD, McConnell D, et al. Antimullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition. J Clin Endocrinol Metab 2008;93:3478-3483.
15. Harlow SD, Crawford S, Dennerstein L, Burger HG, Mitchell ES, Sowers MF. Recommendations from a multi-study evaluation of proposed criteria for staging reproductive aging. Climacteric 2007;10:112-119. (Pubitemid 46482175)
16. Hale GE, Zhao X, Hughes CL, Burger HG, Robertson DM, Fraser IS. Endocrine features of menstrual cycles in middle and late reproductive age and the menopausal transition classified according to the Staging of Reproductive Aging Workshop (STRAW) staging system. J Clin Endocrinol Metab 2007;92:3060-3067. (Pubitemid 47236371)
17. Hale GE, Hughes CL, Burger HG, Robertson DM, Fraser IS. Atypical estradiol secretion and ovulation patterns caused by luteal out-of-phase (LOOP) events underlying irregular ovulatory menstrual cycles in the menopausal transition. Menopause 2009;16:50-59.
18. O'Connor KA, Ferrell R, Brindle E, et al. Progesterone and ovulation across stages of the transition to menopause. Menopause 2009;16:1178-1187.
19. Santoro N, Crawford SL, Lasley WL, et al. Factors related to declining luteal function in women during the menopausal transition. J Clin Endocrinol Metab 2008;93:1711-1721. (Pubitemid 351656509)
20. Santoro N, Brown JR, Adel T, Skurnick JH. Characterization of reproductive hormonal dynamics in the perimenopause. J Clin Endocrinol Metab 1996;81:1495-1501. (Pubitemid 26118582)
21. Moen MH, Kahn H, Bjerve KS, Halvorsen TB. Menometrorrhagia in the perimenopause is associated with increased serum estradiol. Maturitas 2004;47:151-155. (Pubitemid 38130197)
22. Frohlich KL, Kuh DJ, Hardy R, Wadsworth ME. Menstrual patterns during the inception of perimenopause: what are the predictors and what do they predict? J Womens Health Gend Based Med 2000;9:35-42. (Pubitemid 30148100)
23. Kaufert PA, Gilbert P, Tate R. Defining menopausal status: the impact of longitudinal data. Maturitas 1987;9:217-226. (Pubitemid 17163569)
24. Hale GE, Manconi F, Luscombe G, Fraser IS. Quantitative measurements of menstrual blood loss in ovulatory and anovulatory cycles in middle- and late-reproductive age and the menopausal transition. Obstet Gynecol 2010;115:249-256.
25. Seltzer VL, Benjamin F, Deutsch S. Perimenopausal bleeding patterns and pathologic findings. J Am Med Womens Assoc 1990;45:132-134.
26. Hallberg L, Hogdahl AM, Nilsson L, Rybo G. Menstrual blood loss-a population study. Variation at different ages and attempts to define normality. Acta Obstet Gynecol Scand 1966;45:320-351.
27. Bedford JL, Prior JC, Hitchcock CL, Barr SI. Detecting evidence of luteal activity by least-squares quantitative basal temperature analysis against urinary progesterone metabolites and the effect of wake-time variability. Eur J Obstet Gynecol Reprod Biol 2009;146:76-80.
28. Gallup DG, Stock RJ. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol 1984;64:417-420. (Pubitemid 14073467)
29. Farquhar CM, Lethaby A, Sowter M, Verry J, Baranyai J. An evaluation of risk factors for endometrial hyperplasia in premenopausal women with abnormal menstrual bleeding. Am J Obstet Gynecol 1999;181:525-529. (Pubitemid 29453507)
30. Shankar M, Lee CA, Sabin CA, Economides DL, Kadir RA. Von Willebrand disease in women with menorrhagia: a systematic review. BJOG 2004;111:734-740. (Pubitemid 38869763)
31. Mukhopadhayay S, Bhattacharyya SK, Ganguly RP, Patra KK, Bhattacharya N, Barman SC. Comparative evaluation of perimenopausal abnormal uterine bleeding by transvaginal sonography, hysteroscopy and endometrial biopsy. J Indian Med Assoc 2007;105:624, 626, 628 passim.
32. Verrotti C, Benassi G, Caforio E, Nardelli GB. Targeted and tailored diagnostic strategies in women with perimenopausal bleeding: advantages of the sonohysterographic approach. Acta Biomed 2008;79:133-136.
33. Jones MW KR. New ways of managing endometrial hyperplasia. Contemp Obstet Gynecol 1990;35:36-46.
34. Canavan TP, Doshi NR. Endometrial cancer. Am Fam Physician 1999;59:3069-3077.
35. ACOG PB. Management of anovulatory bleeding. 2004:434-441.
36. Stabinsky SA, Einstein M, Breen JL. Modern treatments of menorrhagia attributable to dysfunctional uterine bleeding. Obstet Gynecol Surv 1999;54:61-72. (Pubitemid 29022520)
37. Chen EC, Danis PG, Tweed E. Clinical inquiries. Menstrual disturbances in perimenopausal women: what's best? J Fam Pract 2009;58:E3.
38. Lethaby A, Augood C, Duckitt K, Farquhar C. Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev 2007:CD000400.
39. Lethaby A, Farquhar C, Cooke I. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev 2000:CD000249.
40. Irvine GA, Cameron IT. Medical management of dysfunctional uterine bleeding. Baillieres Best Pract Res Clin Obstet Gynaecol 1999;13:189-202. (Pubitemid 29353805)
41. WellingtonK,Wagstaff AJ. Tranexamic acid: a reviewof its use in themanagement ofmenorrhagia. Drugs 2003;63:1417-1433. (Pubitemid 36776096)
42. Ip PP, Lam KW, Cheung CL, et al. Tranexamic acid-associated necrosis and intralesional thrombosis of uterine leiomyomas: a clinicopathologic study of 147 cases emphasizing the importance of drug-induced necrosis and early infarcts in leiomyomas. Am J Surg Pathol 2007;31:1215-1224. (Pubitemid 47207126)
43. Davis A, Godwin A, Lippman J, Olson W, Kafrissen M. Triphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleeding. Obstet Gynecol 2000;96:913-920.
44. Casper RF, Dodin S, Reid RL. The effect of 20 ug ethinyl estradiol/1mg norethindrone acetate (Minestrin TM), a low-dose oral contraceptive, on vaginal bleeding patterns, hot flashes, and quality of life in symptomatic perimenopausal women. Menopause 1997;4:139-147. (Pubitemid 127729509)
45. Farquhar C, Brown J. Oral contraceptive pill for heavy menstrual bleeding. Cochrane Database Syst Rev 2009:CD000154.
46. van den Heuvel MW, van Bragt AJ, Alnabawy AK, Kaptein MC. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception 2005;72:168-174. (Pubitemid 41133355)
47. Jick S, Kaye JA, Li L, Jick H. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. Contraception 2007;76:4-7. (Pubitemid 46935110)
48. Jick SS, Hagberg KW, Hernandez RK, Kaye JA. Post-marketing study of ORTHO EVRA and levonorgestrel oral contraceptives containing hormonal contraceptives with 30 mcg of ethinyl estradiol in relation to nonfatal venous thromboembolism. Contraception 2010;81:16-21.
49. Lethaby A, Irvine G, Cameron I. Cyclical progestogens for heavy menstrual bleeding. Cochrane Database Syst Rev 2008:CD001016.
50. Kaunitz AM. Current options for injectable contraception in the United States. Semin Reprod Med 2001;19:331-337. (Pubitemid 34028421)
51. Clark MK, Sowers M, Levy B, Nichols S. Bone mineral density loss and recovery during 48 months in first-time users of depot medroxyprogesterone acetate. Fertil Steril 2006;86:1466-1474. (Pubitemid 44602060)
52. Lethaby AE, Cooke I, Rees M. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev 2005:CD002126.
53. Kaunitz AM, Bissonnette F, Monteiro I, Lukkari-Lax E, Muysers C, Jensen JT. Levonorgestrel-releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol 2010;116:625-632.
54. Irvine GA, Campbell-Brown MB, Lumsden MA, Heikkila A, Walker JJ, Cameron IT. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br J Obstet Gynaecol 1998;105:592-598. (Pubitemid 28293475)
55. Wildemeersch D, Dhont M. Treatment of nonatypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system. Am J Obstet Gynecol 2003;188:1297-1298. (Pubitemid 36589125)
56. Vereide AB, Arnes M, Straume B, Maltau JM, Orbo A. Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia: a study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone. Gynecol Oncol 2003;91:526-533. (Pubitemid 38388145)
57. Blumenthal PD, Dawson L, Hurskainen R. Cost-effectiveness and quality of life associated with heavy menstrual bleeding among women using the levonorgestrel-releasing intrauterine system. Int J Gynaecol Obstet 2011.
58. Shaw RW, Fraser HM. Use of a superactive luteinizing hormone releasing hormone (LHRH) agonist in the treatment of menorrhagia. Br J Obstet Gynaecol 1984;91:913-916. (Pubitemid 14033854)
59. Munro MG. Dysfunctional uterine bleeding: advances in diagnosis and treatment. Curr Opin Obstet Gynecol 2001; 13:475-489. (Pubitemid 33016018)
60. Murphy MF, Wallington TB, Kelsey P, et al. Guidelines for the clinical use of red cell transfusions. Br J Haematol 2001;113:24-31. (Pubitemid 32423296)
61. Lethaby A, Shepperd S, Cooke I, Farquhar C. Endometrial resection and ablation versus hysterectomy for heavy menstrual bleeding. Cochrane Database Syst Rev 2000: CD000329.
62. Gimpelson RJ. Not so benign endometrial hyperplasia: endometrial cancer after endometrial ablation. J Am Assoc Gynecol Laparosc 1997;4:507-511. (Pubitemid 27355222)
63. Horowitz IR, Copas PR, Aaronoff M, Spann CO, McGuire WP. Endometrial adenocarcinoma following endometrial ablation for postmenopausal bleeding. Gynecol Oncol 1995;56:460-463.
64. Goodwin SC, Spies JB, Worthington-Kirsch R, et al. Uterine artery embolization for treatment of leiomyomata: long-term outcomes from the FIBROID Registry. Obstet Gynecol 2008;111:22-33.
65. Agdi M, Tulandi T. Endoscopic management of uterine fibroids. Best Pract Res Clin Obstet Gynaecol 2008;22:707-716. (Pubitemid 351804121)
66. Hesley GK, Felmlee JP, Gebhart JB, et al. Noninvasive treatment of uterine fibroids: early Mayo Clinic experience with magnetic resonance imaging-guided focused ultrasound. Mayo Clin Proc 2006;81:936-942. (Pubitemid 43993485)
67. Taran FA, Hesley GK, Gorny KR, Stewart EA. What factors currently limit magnetic resonance-guided focused ultrasound of leiomyomas? A survey conducted at the first international symposium devoted to clinical magnetic resonance-guided focused ultrasound. Fertil Steril 2010;94:331-334.
68. Stewart EA, Gostout B, Rabinovici J, Kim HS, Regan L, Tempany CM. Sustained relief of leiomyoma symptoms by using focused ultrasound surgery. Obstet Gynecol 2007;110:279-287. (Pubitemid 47356651)
69. De M, Sanford TR, Wood GW. Interleukin-1, interleukin-6, and tumor necrosis factor alpha are produced in the mouse uterus during the estrous cycle and are induced by estrogen and progesterone. Dev Biol 1992;151:297-305.
70. Kjerulff KH, Rhodes JC, Langenberg PW, Harvey LA. Patient satisfaction with results of hysterectomy. Am J Obstet Gynecol 2000;183:1440-1447. (Pubitemid 32061205)
71. Hurskainen R, Teperi J, Rissanen P, et al. Quality of life and cost-effectiveness of levonorgestrel-releasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomised trial. Lancet 2001;357:273-277. (Pubitemid 32120860)
72. Hurskainen R, Teperi J, Rissanen P, et al. Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up. JAMA 2004;291:1456-1463. (Pubitemid 38543736)